Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7577741 | 0.90 | EGFR (0.57) | EGFRERBB2HPGDHTTFBP1 | |
| SCHEMBL7581189 | 0.89 | EGFR (0.49) | EGFRERBB2HPGDHTTMAPT | |
| SCHEMBL7587052 | 0.88 | EGFR (0.54) | EGFRERBB2HPGDHTTFBP1 | |
| SCHEMBL7584441 | 0.84 | EGFR (0.49) | EGFRERBB2HPGDHTTMAPT | |
| SCHEMBL7582302 | 0.81 | EGFR (0.55) | EGFRERBB2HPGDHTTMAPT | |
| SCHEMBL7584793 | 0.81 | EGFR (0.55) | EGFRERBB2HPGDHTTCSNK2A2 | |
| SCHEMBL7575499 | 0.80 | EGFR (0.49) | EGFRERBB2HPGDHTTCSNK2A1 | |
| SCHEMBL7587034 | 0.79 | EGFR (0.53) | EGFRERBB2HPGDHTTFBP1 | |
| SCHEMBL7578478 | 0.78 | EGFR (0.59) | EGFRERBB2HPGDHTTBRAF | |
| SCHEMBL7578338 | 0.77 | EGFR (0.47) | EGFRERBB2HPGDHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082420-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082420-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | PKD1, REN, CYP11B1 | EGFR 1041/4885ERBB2 2419/4885HPGD 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.